Company news

Halozyme Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Halozyme to Host Investor Business Forum and Long-Term Outlook Call

January 11, 2024

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

November 15, 2023

Halozyme reports third quarter 2023 financial and operating results

November 5, 2023

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

November 5, 2023

Halozyme To Report Third Quarter 2023 Financial and Operating Results

October 29, 2023

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

October 18, 2023

Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

October 15, 2023

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

October 15, 2023

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

August 28, 2023

Halozyme reports second quarter 2023 financial and operating results

August 7, 2023

Halozyme To Report Second Quarter 2023 Financial and Operating Results

July 24, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 16, 2023

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

July 12, 2023

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

June 19, 2023

Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Halozyme reports first quarter 2023 financial and operating results

May 8, 2023

Halozyme To Report First Quarter 2023 Financial and Operating Results

April 24, 2023

Halozyme reports fourth quarter and full year 2022 financial and operating results

February 20, 2023

Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results

February 6, 2023

Halozyme Appoints Barbara Duncan to its Board of Directors

February 5, 2023

Halozyme Therapeutics, Inc. announces redemption of 1.25% convertible senior notes due 2024

January 10, 2023

Halozyme Provides 2023 Financial Guidance and Outlook

January 9, 2023

Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Halozyme reports third quarter 2022 financial and operating results

November 7, 2022

Halozyme to Report Third Quarter 2022 Financial and Operating Results

October 24, 2022

Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference

August 31, 2022

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028

August 14, 2022

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

August 14, 2022

Halozyme reports second quarter 2022 financial and operating results

August 8, 2022

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer

August 1, 2022

Halozyme to Report Second Quarter 2022 Financial and Operating Results

July 25, 2022

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy

June 6, 2022

Halozyme Completes Antares Pharma Acquisition

May 23, 2022

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

May 11, 2022

Halozyme Reports First Quarter 2022 Results

May 9, 2022

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

May 2, 2022

Halozyme commences tender offer for all outstanding shares of common stock of antares pharma

April 25, 2022

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

April 12, 2022

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology

March 23, 2022

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis

March 21, 2022

Halozyme Appoints Moni Miyashita to Board of Directors

March 14, 2022

Halozyme reports fourth quarter 2021 and full year results

February 21, 2022

Halozyme to host fourth quarter and full year 2021 financial results webcast and conference call

February 8, 2022

Halozyme Appoints New Chief Financial Officer

February 1, 2022

Halozyme provides 2022 financial guidance and outlook

January 9, 2022

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

January 3, 2022

Halozyme appoints new general counsel

December 12, 2021

Halozyme announces $750 million three-year share repurchase program

December 8, 2021

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

November 30, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 65 decks. Every deck is listed under its year.